ChemoCentryx (CCXI) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ChemoCentryx Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 10, 2016 7:05 AM EDT- Company Announces Exclusive License Agreement with Vifor Pharma to Commercialize Orally Administered Complement 5a Receptor Inhibitor CCX168 in Europe and Certain Other Markets; Agreement Includes $85 Million Upfront, Comprising $60 Million in Cash in Addition to $25 Million Equity Investment -
- Patients Complete Treatment Period in AAV Phase II CLASSIC Trial of CCX168; Top Line Data Expected June 2016 -
- Expecting Data from Pancreatic Cancer Trial of CCX872: Initial Objective Response Rates Mid-year; Initial Progression Free Survival Results in the Second Half of 2016 -
-... More
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets
May 10, 2016 7:02 AM EDT- Vifor Pharma to market drug in selected territories outside the US, ChemoCentryx responsible for worldwide development of CCX168 -
- ChemoCentryx to receive USD 85 million comprising USD 60 million in cash and USD 25 million equity investment; Deal also includes regulatory and commercial milestone payments and royalties on net sales to ChemoCentryx in the Vifor Pharma territories -
- Agreement additionally includes exclusive option to negotiate worldwide license for development and commercialization of CCR2 inhibitor CCX140 -
- ChemoCentryx to Host Conference... More
